Sun’s Generic Doxil Clears FDA; Janssen Uses Alternative Manufacturing Process
This article was originally published in The Pink Sheet Daily
FDA approval of the first generic version of Janssen’s Doxil to curtail drug’s shortage; agency also permits Janssen to use an alternative manufacturing process.
You may also be interested in...
Two years ago, Sun Pharmaceuticals was a key part of FDA’s efforts in helping drug shortages; now FDA has banned imports from one of its plants.
Taro’s strong performance since Sun took a majority stake has complicated the Indian pharma’s merger plans, but analysts say the story may still evolve.
FDA is allowing Sun Pharma Global FZE to import its unapproved liposomal version of doxorubicin, Lipodox, to alleviate a shortage, but has not yet given the drug full approval.